

ASX RELEASE

First IVD Product Sale in Switzerland

Melbourne, Australia, 13 March 2018: [Sienna Cancer Diagnostics Ltd \(ASX:SDX\)](#), a commercial stage, medical technology company focused on the development and commercialisation of innovative cancer-related tests is pleased to announce the first sale of the company's hTERT test in Switzerland through its distribution partner, [Biosystems Switzerland AG](#).

Following the signing of Biosystems Switzerland as the exclusive distributor for Switzerland of Sienna's novel IVD test, the first order by a Swiss laboratory has been delivered. This follows training of Biosystems key personnel by Sienna in late 2017, and evaluation and clinical validation by the customer.

Biosystems Switzerland CEO, Urs Brunner said: "Interest in the hTERT test has been very encouraging. Although urine cytology is non-invasive it has significant limitations in terms of sensitivity, particularly when it comes to low-grade or early-stage bladder cancer. Having a biomarker test that can provide additional clinically significant information for the diagnosing physician, while using the same urine sample collected for cytology, adds real value to the diagnostic process, and pathologists appreciate this."

Sienna is encouraged by the interest shown in the hTERT test in Switzerland: "The team at Biosystems Switzerland has done a great job of generating a pipeline of interested laboratories, several of which are well advanced in evaluating the test for clinical use. This is a key milestone in our ongoing geographical expansion strategy," said Minesh Lalla, Business Development Manager, Sienna Cancer Diagnostics.

ENDS.

For further information, please contact:

Matthew Hoskin, CEO
Sienna Cancer Diagnostics
mhoskin@siennadiagnostics.com.au
+61 3 8288 2141

Scott Newstead
WE Buchan
snewstead@we-buchan.com
+61 3 8866 1218



About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. is an Australian medical technology company, with operations in the United States, Europe and Australia. Sienna's strengths lie in identifying novel technologies then developing and commercialising them to satisfy an unmet clinical / market need. The Company has demonstrated the utility of its product with the help of its global clinical partners. Sienna's primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009. Telomerase is well recognised as a remarkable biomarker used by 85% of cancers to enable immortal cell replication.

The FDA listing of Sienna's first IVD in the United States, and CE marking / IVD registration in Europe and Australia, means the SCD-A7 reagent can be used for clinical diagnostic purposes by pathology laboratories. Clinical pathology laboratories in those regions may now purchase SCD-A7 for use as an in vitro diagnostic test for the presence of hTERT, a component of telomerase. Sienna has made available to pathology laboratories a world-first telomerase-based assay for use on human clinical specimens.

About Biosystems Switzerland AG

Biosystems Switzerland AG is a reseller of medical equipment, devices and consumables for laboratories, with particular focus on the pathology industry. Founded over 20 years ago by Urs Brunner in Zullwil, today the Company's headquarters is in MuttENZ.

